Chugai Pharmaceutical has filed a Japanese regulatory application for Tecentriq (atezolizumab) as adjuvant therapy in ctDNA MRD-positive muscle-invasive bladder cancer, supported by Phase III IMvigor011 trial results showing significant DFS and OS benefits.
Written By: Pharmacally Medical News Desk
Chugai Pharmaceutical Co., Ltd. announced that it has filed a regulatory application with Japan’s Ministry of Health, Labour and Welfare (MHLW) seeking approval for Tecentriq® (atezolizumab) as an additional indication. The company is targeting its use as adjuvant therapy for patients with minimal residual disease (MRD)-positive muscle-invasive bladder cancer (MIBC) following surgery.
The filing reflects growing momentum toward more personalized approaches in bladder cancer treatment, particularly for patients at high risk of recurrence after radical cystectomy.
Focus on High-Risk Patients Identified Through ctDNA
MRD positivity in this setting is determined through circulating tumor DNA (ctDNA) blood testing, which can detect residual cancer cells after surgery. Chugai highlighted that Tecentriq could offer a new treatment option for patients identified as having an elevated recurrence risk based on ctDNA status.
“Muscle-invasive bladder cancer has a high recurrence rate after surgery, underscoring the need to optimize adjuvant treatment based on each patient’s individual risk,” said Dr. Osamu Okuda, President and CEO of Chugai. He added that the company remains committed to securing approval so that patients can receive the most appropriate post-surgical therapy.
Application Supported by Phase III IMvigor011 Trial Results
The regulatory submission is supported by data from the global Phase III IMvigor011 study. This trial evaluated Tecentriq monotherapy versus placebo as adjuvant treatment in patients with ctDNA MRD-positive MIBC.
According to Chugai, the study met both key efficacy goals:
The primary endpoint of disease-free survival (DFS) showed statistically significant and clinically meaningful improvement.
The main secondary endpoint of overall survival (OS) also demonstrated significant benefit.
The safety findings were consistent with Tecentriq’s established profile from earlier studies, with no unexpected concerns reported.
About the IMvigor011 Study
IMvigor011 (NCT04660344) is a global Phase III clinical trial designed to assess the efficacy and safety of Tecentriq in the adjuvant setting for patients with ctDNA MRD-positive muscle-invasive bladder cancer. The trial’s primary endpoint was DFS, while secondary endpoints included OS and overall safety.
Muscle-Invasive Bladder Cancer Remains an Unmet Need
Muscle-invasive bladder cancer represents approximately 25% of all bladder cancer cases. In Japan, the annual incidence is estimated at around 6,000 cases as of 2021.
Despite surgery, recurrence risk remains high, and clinicians continue to face challenges in balancing effective adjuvant treatment with the possibility of unnecessary therapy. Biomarker-driven approaches such as ctDNA testing are increasingly viewed as important tools to guide individualized care.
Tecentriq’s Expanding Role in Oncology
Tecentriq is an immune checkpoint inhibitor targeting PD-L1, a protein that enables tumors to evade immune detection by suppressing T-cell activity. By blocking PD-L1 interactions, Tecentriq may restore immune response against cancer cells.
In Japan, Tecentriq has been available since April 2018 and is currently approved across seven tumor types, including lung cancer, breast cancer, hepatocellular carcinoma, thymic carcinoma, and rare malignancies.
References
Chugai Files for Additional Indication of Tecentriq for the Treatment of Adjuvant Therapy for MRD-Positive Bladder Cancer, 28 January 2026, Jan 28,2026 | Chugai Files for Additional Indication of Tecentriq for the Treatment of Adjuvant Therapy for MRD-Positive Bladder Cancer | News | CHUGAI PHARMACEUTICAL CO., LTD.
Thomas Powles et al, ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer, N Engl J Med 2025;393:2395-2408, https://www.nejm.org/doi/full/10.1056/NEJMoa2511885
A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants with High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy (IMvigor011), ClinicalTrials.gov ID NCT04660344, https://clinicaltrials.gov/study/NCT04660344